Loading...

Principia Biopharma

DB:2K1
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2K1
DB
$707M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • Principia Biopharma has significant price volatility in the past 3 months.
2K1 Share Price and Events
7 Day Returns
-5.2%
DB:2K1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:2K1
-10.2%
DE Biotechs
-6%
DE Market
2K1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Principia Biopharma (2K1) -5.2% -21.3% -8.9% - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 2K1.
  • No trading data on 2K1.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

2K1 Value

 Is Principia Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Principia Biopharma. This is due to cash flow or dividend data being unavailable. The share price is €25.18.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Principia Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Principia Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2K1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.65
NasdaqGS:PRNB Share Price ** NasdaqGS (2019-04-18) in USD $29.64
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Principia Biopharma.

DB:2K1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PRNB Share Price ÷ EPS (both in USD)

= 29.64 ÷ 0.65

45.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Principia Biopharma is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Principia Biopharma is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Principia Biopharma's expected growth come at a high price?
Raw Data
DB:2K1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 45.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-25.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:2K1 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 45.95x ÷ -25.3%

-1.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Principia Biopharma earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Principia Biopharma's assets?
Raw Data
DB:2K1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.12
NasdaqGS:PRNB Share Price * NasdaqGS (2019-04-18) in USD $29.64
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2K1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PRNB Share Price ÷ Book Value per Share (both in USD)

= 29.64 ÷ 7.12

4.16x

* Primary Listing of Principia Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Principia Biopharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Principia Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Principia Biopharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2K1 Future Performance

 How is Principia Biopharma expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-25.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Principia Biopharma expected to grow at an attractive rate?
  • Principia Biopharma's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Principia Biopharma's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Principia Biopharma's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2K1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2K1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -25.3%
DB:2K1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 4.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2K1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2K1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 91 -137 -39 2
2022-12-31 13 -128 -149 2
2021-12-31 25 -94 -88 2
2020-12-31 12 -81 -77 4
2019-12-31 9 -68 -69 5
DB:2K1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 69 -21 5
2018-09-30 46 17 -3
2018-06-30 29 4 -10
2018-03-31 17 15 -19
2017-12-31 5 27 -29
2016-12-31 -25 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Principia Biopharma's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Principia Biopharma's revenue is expected to grow by 4.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2K1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Principia Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.14 -1.14 -1.14 1.00
2022-12-31 -4.22 -3.75 -4.69 2.00
2021-12-31 -2.66 -2.43 -2.88 2.00
2020-12-31 -2.55 -1.70 -3.39 4.00
2019-12-31 -2.57 -2.06 -2.97 5.00
DB:2K1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.65
2018-09-30 -1.60
2018-06-30 -15.82
2018-03-31 -32.24
2017-12-31 -50.37
2016-12-31 -59.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Principia Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Principia Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Principia Biopharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2K1 Past Performance

  How has Principia Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Principia Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Unable to establish if Principia Biopharma's year on year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
  • Unable to compare Principia Biopharma's 1-year earnings growth to the 5-year average as it has been trading publicly for less than 3 years.
  • Principia Biopharma has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Principia Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Principia Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 69.14 4.92 11.46 40.53
2018-09-30 46.37 -2.83 9.28 34.40
2018-06-30 29.32 -9.96 7.72 31.26
2018-03-31 17.28 -19.33 7.08 28.32
2017-12-31 5.25 -28.70 6.44 25.39
2016-12-31 -30.64 4.76 22.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Principia Biopharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Principia Biopharma used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Unable to establish if Principia Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Principia Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Principia Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2K1 Health

 How is Principia Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Principia Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Principia Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Principia Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Principia Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Principia Biopharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Principia Biopharma Company Filings, last reported 3 months ago.

DB:2K1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 169.86 0.00 176.93
2018-09-30 159.09 0.00 188.29
2018-06-30 -9.69 0.00 18.32
2018-03-31 -9.69 0.00 18.32
2017-12-31 -13.36 0.00 41.05
2016-12-31 -10.67 10.36 5.87
  • Principia Biopharma has no debt.
  • Principia Biopharma currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • Principia Biopharma has no debt, it does not need to be covered by operating cash flow.
  • Principia Biopharma has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Principia Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Principia Biopharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2K1 Dividends

 What is Principia Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Principia Biopharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Principia Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Principia Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Principia Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2K1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2K1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Principia Biopharma has not reported any payouts.
  • Unable to verify if Principia Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Principia Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Principia Biopharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Principia Biopharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Principia Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Principia Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Principia Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2K1 Management

 What is the CEO of Principia Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matt Babler
COMPENSATION $1,193,855
AGE 53
TENURE AS CEO 8 years
CEO Bio

Mr. Martin Babler, also known as Matt, PhD serves as the Chief Executive Officer of Principia Biopharma Inc since April 2011. Mr. Babler served as the Chief Executive Officer and President of Talima Therapeutics Inc. since December 2007. He served as Senior Executive at Genentech where he served in various management positions for the past eight years. He served as Vice President of Immunology Sales and Marketing of Genentech Inc. since June 2004. He joined Genentech in 1998 as a Director of Cardiovascular Marketing. During the next several years, he held positions as a Director and a Senior Director of Commercial Development and a Senior Director of Immunology Sales and Marketing. Mr. Babler was responsible for leading the strategic direction of the Immunology commercial area, including the management of sales and marketing efforts for Xolair(R) (Omalizumab) and market preparation for Rituxan(R) (Rituximab) for immune system disorders and product line extensions. He held several positions of increasing responsibility at Eli Lilly and Company. He serves as a Director of the Chief Executive Officer of Principia Biopharma Inc. He served as a Director of ZS Pharma, Inc. from February 10, 2015 to December 16, 2015. He served as a Director of Talima Therapeutics, Inc. He served as Director of Infinity Pharmaceuticals, Inc. since May 2008 until March 6, 2014. Mr. Babler completed basic and advanced studies in pharmaceutical science and received a degree in Pharmacy from the Swiss Federal Institute of Technology in Zurich, Switzerland. Mr. Babler is a graduate of the Executive Development Program at the Kellogg Graduate School of Management.

CEO Compensation
  • Insufficient data for Matt to compare compensation growth.
  • Matt's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Principia Biopharma management team in years:

4.3
Average Tenure
54.5
Average Age
  • The tenure for the Principia Biopharma management team is about average.
Management Team

Alan Colowick

TITLE
Executive Chairman of the Board
COMPENSATION
$248K
AGE
56

Matt Babler

TITLE
CEO & Director
COMPENSATION
$1M
AGE
53
TENURE
8 yrs

Christopher Chai

TITLE
Chief Financial Officer
COMPENSATION
$653K
AGE
51
TENURE
5.2 yrs

Stefani Wolff

TITLE
Chief Development Officer
COMPENSATION
$658K
AGE
56
TENURE
0.7 yrs

David Goldstein

TITLE
Chief Scientific Officer
AGE
52

Roy Hardiman

TITLE
Chief Business Officer
AGE
58
TENURE
4.3 yrs

Betsy Santos

TITLE
Vice President of Human Resources

Dolca Thomas

TITLE
Chief Medical Officer
TENURE
0.5 yrs

Ann Neale

TITLE
Senior Vice President of Development Operations

Liana Wu

TITLE
Senior VP of Commercial & Project Team Leader
Board of Directors Tenure

Average tenure and age of the Principia Biopharma board of directors in years:

2.2
Average Tenure
50.5
Average Age
  • The average tenure for the Principia Biopharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Matt Babler

TITLE
CEO & Director
COMPENSATION
$1M
AGE
53

John Smither

TITLE
Director
TENURE
0.2 yrs

Alan Colowick

TITLE
Executive Chairman of the Board
COMPENSATION
$248K
AGE
56
TENURE
2.2 yrs

Srini Akkaraju

TITLE
Director
AGE
50

Simeon George

TITLE
Director
AGE
41

Jack Taunton

TITLE
Board Observer

Dan Becker

TITLE
Director
AGE
42
TENURE
2.3 yrs

Shao-Lee Lin

TITLE
Director
AGE
51
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Sep 18 Buy Samsara BioCapital LLC Company 18. Sep 18 18. Sep 18 175,000 €14.55 €2,545,708
20. Sep 18 Buy Sofinnova Investment, Inc. Company 18. Sep 18 18. Sep 18 270,000 €14.55 €3,927,663
20. Sep 18 Buy OrbiMed Advisors, L.L.C. Company 18. Sep 18 18. Sep 18 250,000 €14.55 €3,636,725
20. Sep 18 Buy New Leaf Venture Partners, L.L.C. Company 18. Sep 18 18. Sep 18 270,000 €14.55 €3,927,663
20. Sep 18 Buy S.R. One, Limited Company 18. Sep 18 18. Sep 18 270,000 €14.55 €3,927,663
X
Management checks
We assess Principia Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Principia Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2K1 News

Simply Wall St News

2K1 Company Info

Description

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Details
Name: Principia Biopharma Inc.
2K1
Exchange: DB
Founded: 2008
$628,995,153
23,865,451
Website: http://www.principiabio.com
Address: Principia Biopharma Inc.
220 East Grand Avenue,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PRNB Common Stock Nasdaq Global Select US USD 14. Sep 2018
DB 2K1 Common Stock Deutsche Boerse AG DE EUR 14. Sep 2018
Number of employees
Current staff
Staff numbers
65
Principia Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:13
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.